Antiinfectives targeting enzymes and the proton motive force

Xinxin Feng, Wei Zhu, Lici A. Schurig-Briccio, Steffen Lindert, Carolyn Shoen, Reese Hitchings, Jikun Li, Yang Wang, Noman Baig, Tianhui Zhou, Boo Kyung Kim, Dean C. Crick, Michael Cynamon, J. Andrew McCammon, Robert B. Genni, and Eric Oldfield

Department of Chemistry, University of Illinois, Urbana, IL 61801; Department of Biochemistry, University of Illinois, Urbana, IL 61801; Department of Chemistry and Biochemistry, Ohio State University, Columbus, OH 43210; Central New York Research Corporation, Veterans Affairs Medical Center, Syracuse, NY 13210; Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523; Department of Pharmacology and Department of Chemistry & Biochemistry, University of California San Diego, La Jolla, CA 92093; Howard Hughes Medical Institute, University of California San Diego, La Jolla, CA 92093; National Biomedical Computation Resource, University of California San Diego, La Jolla, CA 92093; and Center for Biophysics and Computational Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801

Contributed by J. Andrew McCammon, November 6, 2015 (sent for review September 9, 2015; reviewed by Hiroshi Nikaido and David G. Russell)

There is a growing need for new antibiotics. Compounds that target the proton motive force (PMF), uncouplers, represent one possible class of compounds that might be developed because they are already used to treat parasitic infections, and there is interest in their use for the treatment of other diseases, such as diabetes. Here, we tested a series of compounds, most with known antiinfective activity, for uncoupler activity. Many cationic amphiphiles tested positive, and some targeted isoprenoid biosynthesis or affected lipid bilayer structure. As an example, we found that clomiphene, a recently discovered undecaprenyl diphosphate synthase inhibitor active against Staphylococcus aureus, is an uncoupler. Using in silico screening, we then found that the anti-glioblastoma multi-forme drug lead vacquinol is an inhibitor of Mycobacterium tuberculosis tuberculosis tuberculosinyl adenosine synthase, as well as being an uncoupler. Because vacquinol is also an inhibitor of M. tuberculosis cell growth, we used similarity searches based on the vacquinol structure, finding analogs with potent (~0.5–2 μg/mL) activity against M. tuberculosis and S. aureus. Our results give a logical explanation of the observation that most new tuberculosis drug leads discovered by phenotypic screens and genome sequencing are highly lipophilic (logP ~5.7) bases with membrane targets because such species are expected to partition into hydrophobic membranes, inhibiting membrane proteins, in addition to collapsing the PMF. This multiple targeting is expected to be of importance in overcoming the development of drug resistance because targeting membrane physical properties is expected to be less susceptible to the development of resistance.

There is a need for new antibiotics, due to the increase in drug resistance (1, 2). For example, some studies report that by 2050, absent major improvements in drug discovery and use, more individuals will die from drug-resistant bacterial infections than from cancer, resulting in a cumulative effect on global gross domestic product of as much as 100 trillion dollars (3, 4). To discover new drugs, new targets, leads, concepts, and implementations are needed (5, 6).

Currently, one major cause of death from bacterial infections is tuberculosis (TB) (7), where very highly drug-resistant strains have been found (8). Therapy is lengthy, even with drug-sensitive strains, and requires combination therapies with four drugs. Two recent TB drugs/drug leads (9–11) are TMC207 (bedaquiline (1); Sirturo) and SQ109 (2) (Fig. 1). Bedaquiline (1) targets the Mycobacterium tuberculosis ATP synthase (9) whereas SQ109 (2) has been proposed to target MmpL3 (mycobacterial membrane protein large 3), a trehalose monomycolate transporter essential for cell wall biosynthesis (12). SQ109 (2) is a lipophilic base containing an adamantyl “headgroup” connected via an ethylenic diamine “linker” to a geranyl (C10) “side chain,” and in recent work (13), we synthesized a series of 11 analogs of SQ109 (2) finding that the ethanolamine (3) was more potent than was SQ109 (2) against M. tuberculosis H37Rv [0.063 vs. 0.25 μg/mL minimal inhibitory concentration (MIC)], and that at least one protonatable nitrogen in the linker was essential for activity. The latter observation suggested to us that SQ109 (2) and ethanolamine (3) might have activity as uncouplers, collapsing the proton motive force (PMF; ΔP) used to drive ATP synthesis, because we had observed similar uncoupling effects for lipophilic bases, US Food and Drug Administration (FDA)-approved drugs, in trypanosomatid parasites (14, 15). The PMF is given by Mitchell (16, 17): ΔP = Δψ = ΔzH, where Δψ is the electrical or membrane potential component of ΔP, Aψ is the transmembrane pH gradient, and Z is 2.303RT/F where R is the gas constant, T is temperature (in kelvins), and F is the Faraday constant.

We found with SQ109 and its analogs that the most potent M. tuberculosis cell growth inhibitors investigated did indeed collapse pH gradients and Δψ, as also observed with the lipophilic bases amiodarone (4) (14) and dronedarone (5) (15), antiarhythmia drugs, in trypanosomatid parasites (18), and SQ109 (2) also acts as an uncoupler in Trypanosoma cruzi (19). Amiodarone (4) and dronedarone (5) had little uncoupling activity against host cells. In related work, Li et al. (20) found that other TB drug leads, BM212 (6), THPP-2 (7), Ro 48-8071 (8), the urea AU1235 (9), and the indolecarboxamide 2418 (10), most of which had been proposed to target MmpL3, likewise had activity as uncouplers, collapsing pH gradients, and in some cases were active against the uncoupling agents might be expected to be generally cytotoxic, but many US Food and Drug Administration (FDA)-approved drugs do have activity as uncouplers, in addition to targeting enzymes. There is therefore interest in the discovery of antibiotics that have such multitarget activity. Here, we show that some FDA-approved drugs, such as clofazimine, clomiphene, and bedaquiline, with antiinfective activity act as uncouplers. Using molecular dynamics-based in silico screening, we also discovered that the brain cancer drug lead vacquinol is an uncoupler that inhibits an enzyme involved in the formation of tuberculosis (TB) virulence factors, in addition to driving TB bacteria. Our results indicate strong drug–membrane interactions, and that screening for combined enzyme inhibition plus uncoupler activity will lead to new antibiotic leads.

Author contributions: D.C.C., M.C., J.A.M., R.B.G., and E.O. designed research; X.F., J.A.M., and E.O. wrote the paper. Reviewers: H.N., University of California, Berkeley; and D.G.R., Cornell University. The authors declare no conflict of interest.

To whom correspondence may be addressed. Email: jmccammon@ucsd.edu or rbg@chad.scs.uiuc.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1521988112/-/DCSupplemental.
nonreplicative bacteria found under hypoxic conditions. Several of these compounds also have enzyme targets. For example, SQ109 (2), ethanolamine (3), and Ro 48-8071 (8) have been found (13, 20) to inhibit enzymes involved in menaquinone biosynthesis, particularly the prenyl transferase 1,4-dihydroxy-2-naphthoate octaprenyltransferase (MenA) and human oxidosqualene cyclase (OSC) (21), and bedaquiline (1) is a potent ATP synthase inhibitor, indicating the possibility of multitarget activity for such compounds. These results are of interest because they show that several recently discovered \textit{M. tuberculosis} drug leads can act as uncouplers in addition to targeting one or more enzymes that are essential for bacterial cell growth, with membrane targeting being of particular interest because it might be expected to be less susceptible to the development of resistance than is purely enzyme targeting, and SQ109 (2) does indeed have a low frequency of resistance in \textit{M. tuberculosis} \((\sim 2.55 \times 10^{-11})\) (22). Targeting membrane lipids is also a reason for the low frequency of resistance found with, for example, amphoterocin [which binds to ergosterol in fungi and protozoa (23)], as well as the recently discovered teixobactin, which binds to lipid II/III (24).

In other work by Goldman (25), it has been pointed out that most of the new TB drug leads that have been discovered by phenotypic screens and genome sequencing are highly lipophilic (logP \(~ 5.7\)) bases with membrane targets, which suggested to us the possibility that these drug leads might function by targeting the PMF, as well as membrane proteins. Although targeting the PMF might be expected to be purely mitotoxic, Stock et al. (26) have shown that compounds with logP > 6 have generally low mitotoxicity, which is due, they proposed, to low membrane permeability attributable to accumulation in lipophilic membranes.

Perhaps the most well-known uncoupler is 2,4-dinitrophenol (DNP; 11). DNP functions as a protonophore, a proton-translocating molecule, and analogs such as niclosamide (12) and nitazoxanide (13) [active form, tizoxanide (14)] are used clinically: niclosamide (12) to treat tapeworm infections (27) and nitazoxanide (13) to treat infections due to \textit{Giardia lamblia} (28) and \textit{Cryptosporidium parvum}. Nitazoxanide (13) has also been in clinical trials for the treatment of \textit{Helicobacter pylori} and \textit{Clostridium difficile} infections. Interestingly, SQ109 (2) has similar activity against both organisms (29), and with \textit{H. pylori}, SQ109 (2) once again has a very low \((\approx 10^{-12})\) frequency of resistance (29). In addition, nitazoxanide (13) has been found to kill both replicating and nonreplicating \textit{M. tuberculosis} (30–33), and Nathan and coworkers (30, 31) were unable to develop resistant colonies using up to \(10^{12}\) cfu, proposing a dual “PMF + unknown target” mechanism of action. Niclosamide (12) has been proposed
as a lead for the treatment of type II diabetes (34), and it is also an inhibitor of breast cancer stem-like cells (35) and an inhibitor of *Pseudomonas aeruginosa* quorum sensing (36). There has also been very recent interest in the development of DNP analogs such as DNP methyl ether (37), for treating diabetes, and of controlled-release DNP formulations (38) as mild hepatic mitochondrial uncouplers for treating hypertriglyceridemia, insulin resistance, hepatic steatosis, and diabetes. Niclosamide (12) and tizoxanide (14) are both FDA-approved, and closantel (15) is an anthelmintic uncoupler in veterinary use, and all could provide leads for new and improved inhibitors that target other pathogens. There has also been considerable renewed interest (39) in the use of pyrazinoic acid (16), which functions, at least in part, as a protonophore uncoupler, for treating TB (39, 40), stimulating our interest in discovering new TB drug leads with uncoupler activity.

In this work, we carried out three main types of investigation. First, we investigated the uncoupling effects of 21 compounds (primarily known drugs or drug leads) on uncoupling (ΔpH/Δψ collapse) in bacterial inverted membrane vesicles (IMVs) and in porcine mitochondria. Second, we investigated drug–membrane interactions using differential scanning calorimetry (DSC) and electron paramagnetic resonance (EPR) spectroscopy. Third, we used molecular dynamics (MD) structure-based in silico screening and structure-similarity searches to find prenyl synthase inhibitors with uncoupler activity, leading finally to a consideration of the future prospects for discovering new "enzyme + uncoupler" antifungal drug leads.

**Results and Discussion**

**Targeting the PMF.** We first investigated two TB drugs that seemed likely to act, at least in part, as protonophore uncouplers: clofazimine (17) (Fig. 1) and TMC207 (1), which have similar logP and pKa values to each other as well as to amiodarone (4, Table 1), a known uncoupler we worked on previously.

Clofazimine (17) was originally developed as a TB drug (41) but later was used extensively (42) in treating leprosy, caused by another *Mycobacterium*, *Mycobacterium leprae*. There have been several mechanisms of action demonstrated or proposed for clofazimine (17), including a redox cycling reaction involving the generation of reactive oxygen species (43), and clofazimine is currently of interest for use in combination therapies with benzothiazinones (44). We used the sealed, inside-out IMV assay previously to investigate SQ109 (2) (13) with 9-amino-6-chloro-2-methoxyacridine (ACMA) as a pH-sensitive fluorescence probe of the pH gradient, ΔpH (computed as illustrated in Fig. S1). Using ATP hydrolysis through the ATP synthase, protons are driven inside the membrane vesicles, protonated ACMA accumulates, and its fluorescence is self-quenched. The same effect is seen with addition of succinate/O2, where, again, H+ is pumped into the vesicles. Addition of clofazimine (17) caused rapid increases in ACMA fluorescence in both succinate-oxidation and ATP-powered assays, as shown in Fig. 2A and B. These results are very similar to the results we reported previously for SQ109 (2) (13), as well as to the results we found for TMC207 (1) in the same assays (Fig. 2C and D). TMC207 (1) is thought to target the ATP synthase in *M. tuberculosis*, but in recent work, it has also been proposed to act as an uncoupler, targeting again the ATP synthase (45). However, there is expected to be a significant protonophore contribution to its activity because clofazimine (17) (not thought to target the ATP synthase) and TMC207 (1) have almost identical logP, pKa, and computed charge values (at pH 7.4) (Table 1), even though the chemical structures are completely different. For clofazimine (17), the values are logP = 7.3, pKa = 9.29, logD = 5.23, and charge = 0.99; for TMC207 (1), the values are logP = 7.13, pKa = 8.91, logD = 5.42, and charge = 0.98 (Table 1). It thus seems likely that clofazimine (17), as well as TMC207 (1), can act, at least in part, in a similar manner to the potent anionic protonophores, such as carbonyl cyanide m-chlorophenyl hydrazine.
some of which have activity against charge delocalization is likely to contribute to membrane solubility. What is also of interest with clofazimine and TMC207 is that it is an example of a cationic protonophore (46) with extensive charge delocalization, as found in the 4-piperidinopyridine un- nophore uncouplers, as well as neutral species (e.g., AU1235), so we also possible, however, that there could be many anionic proto- phores that act as cationic protonophore uncouplers and collapse Δψ. Molecular property calculations were carried out using Marvin ChemAxon (https://www.chemaxon.com/marvin/sketch/index.php) and Chemicalize (www.chemicalize.org). All structures are shown in Fig. 1. AMIO, amiodarone; CFZ, clofazimine; PLAT, platensimycin; RAL, raloxifene; SMX, sulfamethoxazole; TAM, tamoxifen; TMP, trimethoprim.

In recent work, we (49) and others (50, 51) identified several anionic, bacterial cell growth inhibitors that, in addition to inhibiting bacteria-specific enzyme targets, might have activity as uncouplers, as expected for lipophilic, weak acid, classic uncouplers like CCCP and DNP. We first investigated seven compounds with known antibacterial activity and a diverse range of proposed protein targets. In all cases, we anticipated a negative net charge (pH 7.4). The compounds were the benzoic acid BPH1463 (23) (Fig. 1), which inhibits undecaprenyl diphosphate synthase (UPPS) (52); the benzoic acid BPH11276 (24) developed by Pharmacia, which has been proposed to target transcription/translation (50) but also inhibits UPS (49); the diketoacid BPH1330 (25) that inhibits S. aureus UPS; S. aureus dehydroxylase (CrtM) (52), and S. aureus cell growth, as well as inducing formation of neutrophil extracellular traps (52); the dihydropyridin-2-one-3-carboxamide BPH1899 (26) developed by Novartis, which inhibits Streptococcus pneumoniae UPS, S. pneumoniae, and S. aureus cell growth (51); platensimycin (27), and sulfamethoxazole (28). The phenol platensimycin (27) is an antibiotic that inhibits fatty acid biosynthesis (53), as well as having antidiabetic activity (54). There is also renewed interest in sulfamethoxazole (28)/trimethoprim (29) combined activity against M. tuberculosis (55), and sulfamethoxazole has a sulfonamide that can act as a weak acid. However, of these compounds, only the benzoate (23) had significant activity as a protonophore (Table 1), due perhaps to relatively unfavorable interactions of most species with anionic membrane lipids.

In addition to cationic and anionic uncouplers, there are several known neutral uncouplers. In early work, it was found that in the industrial preparation of the herbicide Diuron [3-(3,4- dichlorophenyl)-1,1-dimethylurea], there was an impurity that had potent activity as an uncoupler: N,N'-bis(3,4-dichloro- phenyl)urea (30) (56). In later work (57), it was found that

**Fig. 2.** Effects of drugs/drug leads on the PMF. ACMA assays with EcIMV: clofazimine (17), succinate/O2 substrate (A); clofazimine (17)/ATP-powered PMF (B); TMC207 (1)clofazimine (C); and TMC207 (1)/ATP (D). Methods used are the same as in the study by Li et al. (13). EC50 results for all compounds investigated are given in Table 1. A, unitary animals. (E) Heat map of correlation coefficients between uncoupling activities [ΔpH in EcIMV and MsIMV, Δψ in EcIMV, Δψ in mitochondria (mito)], molecular properties (logD, pKa, charge), and cell growth inhibition [M. tuberculosis (Mtb)]. (F) Heat map of uncoupling activities (ΔpH in EcIMV and MsIMV, Δψ in EcIMV), molecular properties (logD, charge), and cell growth inhibition (Mtb) for Mtb inhibitors shown in Table 1. High activities refer to small ΔpH/Mtb EC50 values, and high Δψ collapse/logD charge. Molecular property calculations were carried out using Marvin ChemAxon (https://www.chemaxon.com/marvin/sketch/index.php) and Chemicalize (www.chemicalize.org). All structures are shown in Fig. 1. AMIO, amiodarone; CFZ, clofazimine; PLAT, platensimycin; RAL, raloxifene; SMX, sulfamethoxazole; TAM, tamoxifen; TMP, trimethoprim.
**Mechanisms of Action of Uncoupling.** We next tested all compounds for their effects on the membrane potential, ΔΨ, in E. coli IMVs using oxonol VI as the fluorescence probe and on Δψ in porcine mitochondria using 3,3-dipropylthiadicarbocyanine iodide (DiSC3(5)) fluorescence as the probe (61) (Table 1). Most compounds tested were active in Δψ collapse in E. coli IMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on ΔpH/Δψ collapse in IMVs, it can be seen from the heat map shown in Fig. 2F that ΔΨ collapse (ΔpH E. coli IMV and ΔΔΨ MSIMV) and E. coli Δψ collapse (Δψ) are highly correlated (red, Pearson R values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The R value for E. coli ΔΨ collapse in E. coli IMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on ΔpH/Δψ collapse in IMVs, it can be seen from the heat map shown in Fig. 2F that ΔΨ collapse (ΔpH E. coli IMV and ΔΔΨ MSIMV) and E. coli Δψ collapse (Δψ) are highly correlated (red, Pearson R values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The R value for E. coli ΔΨ collapse in E. coli IMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on ΔpH/Δψ collapse in IMVs, it can be seen from the heat map shown in Fig. 2F that ΔΨ collapse (ΔpH E. coli IMV and ΔΔΨ MSIMV) and E. coli Δψ collapse (Δψ) are highly correlated (red, Pearson R values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The R value for E. coli ΔΨ collapse in E. coli IMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on ΔpH/Δψ collapse in IMVs, it can be seen from the heat map shown in Fig. 2F that ΔΨ collapse (ΔpH E. coli IMV and ΔΔΨ MSIMV) and E. coli Δψ collapse (Δψ) are highly correlated (red, Pearson R values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The R value for E. coli ΔΨ collapse in E. coli IMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on ΔpH/Δψ collapse in IMVs, it can be seen from the heat map shown in Fig. 2F that ΔΨ collapse (ΔpH E. coli IMV and ΔΔΨ MSIMV) and E. coli Δψ collapse (Δψ) are highly correlated (red, Pearson R values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The R value for E. coli ΔΨ collapse in E. coli IMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on ΔpH/Δψ collapse in IMVs, it can be seen from the heat map shown in Fig. 2F that ΔΨ collapse (ΔpH E. coli IMV and ΔΔΨ MSIMV) and E. coli Δψ collapse (Δψ) are highly correlated (red, Pearson R values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The R value for E. coli ΔΨ collapse in E. coli IMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on ΔpH/Δψ collapse in IMVs, it can be seen from the heat map shown in Fig. 2F that ΔΨ collapse (ΔpH E. coli IMV and ΔΔΨ MSIMV) and E. coli Δψ collapse (Δψ) are highly correlated (red, Pearson R values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The R value for E. coli ΔΨ collapse in E. coli IMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on ΔpH/Δψ collapse in IMVs, it can be seen from the heat map shown in Fig. 2F that ΔΨ collapse (ΔpH E. coli IMV and ΔΔΨ MSIMV) and E. coli Δψ collapse (Δψ) are highly correlated (red, Pearson R values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The R value for E. coli ΔΨ collapse in E. coli IMVs, but very few were active in porcine mitochondia (Table 1).
In both the DPPC and DMPA systems, however, there are decreases in the thermal transition temperatures in the presence of SQ109 (2), which may be expected to increase membrane lipid disorder/fluidity and, arguably, uncoupler activity.

We also investigated the effects of four drug molecules, SQ109 (2), amiodarone (4), clofazimine (17), and AU1235 (9), on lipid order/dynamics, using the EPR spin label approach we used previously to investigate the effects of cholesterol on lipid membranes (64). Fig. 3 H and I show variable temperature results for DPPC + SQ109 (2) (20 mol%) at pH 5, pH 7, and pH 9. (G) Comparison of pH dependence of logD, ΔTm, IC50 of ΔpH, and M. smegmatis cell growth inhibition of SQ109. Drug concentration is 20 mol% total lipids, excess water. (F) Variable temperature (VT) X-band (9.14 GHz) CW-EPR spectra for DPPC lipid with 0.1% 5-DOXYL stearate methyl ester (5-DSME) spin label, with or without 20 mol% SQ109 (2), amiodarone (4), clofazimine (17), or AU1235 (9). (I) VT X-band (9.14 GHz) CW-EPR spectra for DMPA lipid with 0.1% 5-DOXYL stearic acid (5-DSA) spin label, with or without compound SQ109 (2), amiodarone (4), clofazimine (17), or AU1235 (9). The red boxes in H and I indicate phase transitions of lipids. The red arrows in H indicate evidence for more than a single spectral component.

In both the DPPC and DMPA systems, however, there are decreases in the thermal transition temperatures in the presence of SQ109 (2), which may be expected to increase membrane lipid disorder/fluidity and, arguably, uncoupler activity.

We also investigated the effects of four drug molecules, SQ109 (2), amiodarone (4), clofazimine (17), and AU1235 (9), on lipid order/dynamics, using the EPR spin label approach we used previously to investigate the effects of cholesterol on lipid membranes (64). Fig. 3 H and I show variable temperature results for DPPC + SQ109 (2) (20 mol%) at pH 5, pH 7, and pH 9. (G) Comparison of pH dependence of logD, ΔTm, IC50 of ΔpH, and M. smegmatis cell growth inhibition of SQ109. Drug concentration is 20 mol% total lipids, excess water. (F) Variable temperature (VT) X-band (9.14 GHz) CW-EPR spectra for DPPC lipid with 0.1% 5-DOXYL stearate methyl ester (5-DSME) spin label, with or without 20 mol% SQ109 (2), amiodarone (4), clofazimine (17), or AU1235 (9). (I) VT X-band (9.14 GHz) CW-EPR spectra for DMPA lipid with 0.1% 5-DOXYL stearic acid (5-DSA) spin label, with or without compound SQ109 (2), amiodarone (4), clofazimine (17), or AU1235 (9). The red boxes in H and I indicate phase transitions of lipids. The red arrows in H indicate evidence for more than a single spectral component, consistent with the considerable broadening of the transition seen in DSC. Similar results are seen with DMPA with the four compounds, as shown in Fig. 3 I. The DSC and EPR spin label results therefore both indicate that the largest effects on membrane structure are seen with the localized charge uncouplers, whereas the delocalized charge and neutral species have much smaller effects on bilayer structure.

Overall then, the results described here and in the previous sections indicate that many TB drugs and drug leads are quite potent uncouplers. In some cases, as discussed in the next section, these compounds also act as enzyme inhibitors, providing the possibility of multisite targeting. This possibility is, of course, of importance because most antibiotics that have been relatively resistant to the development of drug resistance over time have more than one target. We next consider one class of enzymes that might...
be particularly good targets for inhibitors that are also uncouplers: the isoprenoid or prenyl biosynthesis enzymes.

Targeting Prenyl Synthases. As a class, prenyl synthases are important drug targets. In addition, several protonophore uncouplers are known to act as prenyl synthase inhibitors. A plausible reason for this uncoupler/inhibitor relation is that most prenyl synthases use either cationic (transition state/reactive intermediate) or anionic (substrate/product) headgroups and they have substrates/products with large hydrophobic side chains. Therefore, cationic or anionic uncouplers with charged-hydrophobic structural characteristics can be well accommodated by the polar-nonpolar active site pockets of prenyl synthases, and may have high activity as competitive inhibitors. By way of some examples, we show in Fig. 4 the structures of six prenyl synthase drug targets, together with known enzyme inhibitors that are also uncouplers [several of which are FDA-approved drugs (4, 36) or are in clinical trials (2)]. All six proteins have polar-nonpolar active-site pockets that correlate with the involvement of charged-hydrophobic substrates/products or transition state/reactive intermediates, as shown in Fig. 4.

Fig. 4A is a Phyre2 (65) model prediction for MenA [based on UbiA (66); Protein Data Bank (PDB) ID code 4OD5]. SQ109 analog 3 inhibits M. smegmatis MenA with an IC₅₀ of 4 μM and E. coli MenA with an IC₅₀ of 400 nM (13). Fig. 4B shows the structure of S. aureus dehydrogenase synthase, CrtM (PDB ID code 4EAI) and its inhibitor SQ109 (67), and Fig. 4C shows the structure of human OSC [a model for the trypanosomatid OSC drug targets; PDB ID code 1W6J (21)]. MenA and CrtM both have typical all-α-helical structures found in trans-prenyl synthases, whereas OSC has the two-domain structure found in the class II terpene cyclases. The proteins shown in Fig. 4 D–F all contain the cis-isoprenoid biosynthesis enzyme fold: UPPS [PDB ID code 2E98 (68)] in Fig. 4D; decaprenyl diphosphate synthase [DPPS; PDB ID code 2VG3 (69)] in Fig. 4E; and Rv3378c, tuberculosis adenosine (3′′′′)-diphosphate (3′′′′)-ribose synthase [PDB ID code 3WQM (70)] in Fig. 4F. Rv3378c is of interest because it is a target for antivirulence-based therapeutics for TB. As one example of a UPPS uncoupler-inhibitor, we reported in recent work that the fertility drug clomiphene also had activity against S. aureus and that a major target was UPPS (71). What is interesting about the clomiphene (36) structure is that it is remarkably similar to the structure of tamoxifen (20), which itself has antifertility activity. We find an EC₅₀ of 1.2 μM for clomiphene (in the EcIMV assay; Table 1) in comparison to 0.39 μM for the potent uncoupler CCCP and 0.45 μM for tamoxifen. Clomiphene also has an 8 μg/mL MIC against Enterococcus faecium (72) and a 0.22 μM IC₅₀ against liver stage malaria parasites (73), suggesting that there may be dual target activity in several pathogens. So, uncoupler-inhibitors are known for MenA, CrtM, OSC, DPPS, and UPPS, whereas uncoupler-inhibitors for Rv3378c have yet to be discovered.

Rv3378c catalyzes the formation of TbAd (74) (Fig. 5A) and related compounds (75). Transposon mutants of Rv3378c show inhibited phagosomal acidification, and Rv3378c is necessary for production of TbAd and related metabolites. Therefore, it is likely that one of the TbAd compounds controls intravacuolar pH (76). Here, we initially sought to discover inhibitors of Rv3378c that were also uncouplers, reasoning that the combination of direct uncoupling (as with SQ109) and antivirulence activity would be a good approach to killing intracellular M. tuberculosis. We thus carried out an in silico screen of a library of 1,013 compounds [from National Cancer Institute (NCI) diversity set III] using the MD-based structures reported previously (77). The X-ray structure of Rv3378c with a bound inhibitor is shown in Fig. 5B, together with one snapshot from an MD trajectory.

We tested 39 compounds (Fig. S3) from the in silico screen for Rv3378c inhibition activity using tuberculosis diphosphate and 3H-adenosine as substrates. The structures of the compounds tested are shown, together with their IC₅₀ values against Rv3378c, in Fig. S3. Compounds that failed the pan-assay interference compounds (PAINS) (78) test are shown in red in Fig. S3. The most active compound was the ethanolamine NSC13316 (37), which had an IC₅₀ of 2.7 μM in Rv3378c inhibition (Fig. S4). Surprisingly, NSC13316 (37) has already been reported (79) to potently inhibit the growth of M. tuberculosis, with an MIC of 1.6 μg/mL (4.5 μM). This effect is not expected for a virulence-targeting drug lead. Moreover, NSC13316 (37), now known as vacquinol-1, has activity against glioblastoma multiforme (GBM) cancer cells (80), both in vitro and in vivo, and is thought to kill these tumor cells by an unusual mechanism involving a decrease in ATP levels and extensive vacuolization (80). NSC13316 (37) is, therefore, a potentially interesting new antifluoretic multitarget drug lead.

Vacquinol Analogs as Antiinfective Drug Leads. The observation that vacquinol is active against M. tuberculosis growth, as well as the antivirulence target Rv3378c, was of interest, so we next carried out a structure similarity search based on NSC13316 (37) and obtained 13 analogs from the NCI/Developmental Therapeutics Program Open Chemical Repository (dtp.cancer.gov/). We then tested NSC13316 (37) and these analogs (Fig. S5) for uncoupling activity in the EcIMV and MsIMV assays, finding that vacquinol (37) had an ≈12–13 μM IC₅₀ (Fig. S4). Results for the analogs are summarized in Table S1.
The vacquinol class of compounds, 2-piperidinyl-4-quinoline-methanols, were originally developed as antimalarials (81, 82), and in addition to their activity against *M. tuberculosis* and brain cancer cells, they can inhibit efflux pumps and are of interest in combating multidrug resistance in cancer cells (79, 83, 84), suggesting the possibility that their uncoupling effects could contribute to a diverse range of activities. The fact that vacquinol also has promising in vivo activity against GBM, a good in vivo pharmacokinetic profile, oral bioavailability, and favorable overall preclinical characteristics (80), in addition to killing *M. tuberculosis*, makes it an interesting lead for antiinfective development.

We therefore next tested the 13 vacquinol analogs for growth inhibition activity against *M. tuberculosis* H37Rv and *M. tuberculosis* Erdman, as well as against another bacterium, *S. aureus*, and against the yeast *Saccharomyces cerevisiae*, basically to see if there were general growth inhibitory effects against bacteria and a fungus. We found that vacquinol and its analogs were quite potent in cell growth inhibition against each of these microorganisms, with the best IC50s for *M. tuberculosis* H37Rv, *M. tuberculosis* Erdman, *S. aureus*, and *S. cerevisiae* being 0.53, 1.5, 1.4, and 3.4 μg/mL, respectively (Table S1). Moreover, we found that the uncoupling activity of these compounds (EcIMV assay) correlated well with their bacterial and yeast cell growth inhibition potency, as well as with the growth inhibition of GBM cancer cells (Fig. 5C), with coefficients of cross-correlation larger than 0.7, suggesting the possibility that uncoupling is a contributor to the antibacterial/antifungal/anticancer activity of the vacquinol series.

![Fig. 5. Vacquinol and its analogs as inhibitors for Rv3378c activity and bacterial cell growth.](image)

**Fig. 5.** Vacquinol and its analogs as inhibitors for Rv3378c activity and bacterial cell growth. (A) Reaction catalyzed by Rv3378c. (B) MD simulation/in silico screening approach used to identify Rv3378c inhibitors, showing the X-ray structure (Left), MD snapshot (Center), and in silico hit (Right). (C) Heat map of correlation coefficients between uncoupling activity (ΔpH EcIMV) and antibacterial (Mtb, MtbE, Ms, Sa)/antifungal (Sc)/anticancer (GBM) activities of the vacquinol series. Structures are shown in Fig. S5. Ms, *M. smegmatis*; Sa, *S. aureus*; Sc, *S. cerevisiae*.

![Fig. 6. Schematic illustration of antiinfective drugs/drug leads that target both enzymes and the PMF.](image)

**Fig. 6.** Schematic illustration of antiinfective drugs/drug leads that target both enzymes and the PMF. CFZ, clofazimine; CLO, clomiphene; LPZ, lansoprazole; LPZS, lansoprazole sulfide; PZA, pyrazinamide; PZOA, pyrazinoic acid; ROS, reactive oxygen species; VAC, vacquinol.
Future Prospects for Enzyme/Uncoupler Drug Leads. The results we have presented above show that numerous FDA-approved drugs and other drug leads have activity as uncouplers. Pure uncouplers (without enzyme targets) are generally not expected to be good drug leads, although, as noted in the Introduction, some antiparasitics function in this way, plus there is considerable interest in the development of DNP prodrugs/formulations for treating diabetes, insulin resistance, and hepatic steatosis. Because we find that TB drugs like clofazimine, bedaquiline, and SQ109 all have protonophore uncoupler activity, it seems likely that one route to finding new leads will be to investigate bedaquiline, and SQ109 all have protonophore uncoupler activity, and uncoupler activity. It is also possible that prodrug uncouplers can be produced in some cases in much the same way that DNP-methyl ether is being developed to treat diabetes, or the fact that nitazoxanide (14) is a prodrug for tizoxanide (14). As an example, with M. tuberculosis, it has recently been shown that the heartburn/proton pump inhibitor drug lansoprazole is metabolized to lansoprazole sulfide (structures in Fig. 6), which has potent activity against M. tuberculosis inside macrophages (85), and similar antibacterial effects are seen with omeprazole (which is reduced to the active sulfide) in Helicobacter pylori (86), as well as with rabeprazole (87, 88). Lansoprazole, omeprazole, and rabeprazole are all proton pump inhibitors that contain benzimidazole groups with sulfoxide substituents. They can be reduced to sulfides, and this reduction correlates with a predicted large increase in benzimidazole pKₐ values (from ~1 for the highly electron-donating sulfide to ~4.2 for the electron-donating sulfides), and this increased basicity would increase uncoupling activity (as would an increase in logP of ~1 unit). We tested lansoprazole, lansoprazole sulfide, and rabeprazole sulfide for uncoupling activity in the EcIMV assay. Results are shown in Fig. 6. Clomiphene, known to target cell wall biosynthesis by inhibiting UPPS, was an uncoupler, expected to lead to resistance-resistance. Overall, the results are of broad general interest because we find that many lipophilic, cationic species have activity against bacteria and that they act, at least in part, as uncouplers. In addition, many of the vacquinol class of GBM cell growth inhibitors are also uncouplers, and some have promising activity against M. tuberculosis and S. aureus. The fact that the new M. tuberculosis drugs/drug leads bedaquiline and SQ109, as well compounds such as clofazimine (where there is renewed interest in treating M. tuberculosis), are protophosphate uncouplers that also have activity against (or are activated by) enzyme targets makes it likely that this multitargeting will contribute to overall activity and resistance-resistance, making the further development of such multitarget leads of interest.

Methods
M. smegmatis, S. cerevisiae, S. aureus, and M. tuberculosis growth inhibition assays; the porcine liver mitochondrion Δψ assay; Δψ and Δψ assays with IMV; MD simulation of Rv3378c; Rv3378c inhibition; DSC; and EPR were performed as described previously (13, 70, 77, 91, 92), with full details given in SI Methods.

ACKNOWLEDGMENTS. We thank Prof. Tsurumoto Hoshino for providing tuberculosis diphosphoryl and Prof. David B. Moody for his helpful comments. This work was supported by the US Public Health Service (NIH Grant GM065307), by a Harriet A. Harlin Professorship (to E.O.), and by the University of Illinois Foundation/Oldfield Research Fund. Work at the University of California San Diego was supported, in part, by the NIH, National Science Foundation, Howard Hughes Medical Institute, the National Biomedical Computation Resource (NBNR), and the San Diego Supercomputer Center (SDSC).

Conclusions
We tested a series of cationic, neutral, and anionic compounds for uncoupler activity in M. smegmatis and E. coli IMV assays and in porcine liver mitochondria. The most active compounds in the IMV assays were cationic amphiphatic drugs. These drugs also inhibited M. tuberculosis and M. smegmatis cell growth. Clofazimine (17) and TMC207 (1) were particularly active uncouplers, comparable to CCCC. We investigated drug–membrane interactions using DSC and EPR, finding that lipophilic cations with localized charges had large effects on the lipid phase transition, whereas delocalized charge species [clofazimine (17) and the neutral uncoupler AU1235 (9)] had essentially no effects. Several uncouplers were inhibitors of isopropenyl biosynthesis enzymes, so we then used in silico screening to discover new inhibitors of TbAd synthase that were also uncouplers. We found that vacquinol (37) was one such compound, a result of interest because vacquinol is a new drug lead for treating GBM and also has direct killing activity against M. tuberculosis. These observations led to the discovery of more potent analogs with activity against M. tuberculosis and S. aureus that also likely function, at least in part, as uncouplers. We also discovered that the new S. aureus growth inhibitor clomiphene, known to target cell wall biosynthesis by inhibiting UPPS, was an uncoupler, expected to lead to resistance-resistance. Overall, the results are of broad general interest because we find that many lipophilic, cationic species have activity against bacteria and that they act, at least in part, as uncouplers. In addition, many of the vacquinol class of GBM cell growth inhibitors are also uncouplers, and some have promising activity against M. tuberculosis and S. aureus. The fact that the new M. tuberculosis drugs/drug leads bedaquiline and SQ109, as well compounds such as clofazimine (where there is renewed interest in treating M. tuberculosis), are protophosphate uncouplers that also have activity against (or are activated by) enzyme targets makes it likely that this multitargeting will contribute to overall activity and resistance-resistance, making the further development of such multitarget leads of interest.

References


Supporting Information

Feng et al. 10.1073/pnas.1521988112

SI Methods

General Methods. All chemicals were reagent grade. 1H NMR and 13C NMR spectra were obtained on a Varian Unity spectrometers at 400 and 500 MHz for 1H and at 100 and 125 MHz for 13C. Elemental analyses were carried out in the University of Illinois Microanalysis Laboratory. HPLC/MS analyses were performed by using an Agilent LC/MSD Trap XCT Plus system (Agilent Technologies) with an 1100 series HPLC system, including a degasser, an autosampler, a binary pump, and a multiple wavelength detector. All compounds were ≥95% pure as determined by elemental analysis or analytical HPLC/MS analysis and were also characterized by 1H nuclear magnetic resonance spectroscopy (NMR) and high resolution mass spectrometry (HRMS).

*M. smegmatis*, *S. cerevisiae*, *S. aureus*, and *M. tuberculosis* Growth Inhibition Assay. IC50 values for *M. smegmatis* growth inhibition were determined by using a microbroth dilution method. A stationary starter culture of *M. smegmatis* was diluted to an OD600 of ~0.001 with fresh 7H9 medium supplemented with 10% (vol/vol) albumin dextrose catalase (ADC) and 4% (vol/vol) glycerol to give a working solution; 200 μL of working solution was then transferred to each well of a 96-well, flat-bottom culture plate (Corning, Inc.). Inhibitors were then added at 0.2 mM and threefold serial-diluted to 30 nM. Plates were incubated for 5 h at 37 °C, and the A at 600 nm was determined. A nonlinear regression analysis was carried out using Origin 6.1 (OriginLab Corporation) to obtain the IC50 values. *S. cerevisiae* and *S. aureus* IC50 values were obtained similarly, except for different growth media and incubation times: yeast peptone dextrose (YPD) medium and 36 h of growth for *S. cerevisiae* and tryptic soy broth (TSB) medium and 16 h of growth for *S. aureus*. The *M. tuberculosis* growth inhibition assay was performed as described previously (91).

ΔpH and Δψ Assay with IMV. The preparation of IMVs, assay for ATP- or succinate-driven proton translocation, and determination of Δψ collapse in IMVs were as reported previously (13).

Porcine Liver Mitochondria Δψ Assay. Mitochondria were prepared from fresh porcine liver according to a reported protocol (92), with 225 mM mannitol, 75 mM sucrose, 10 mM KCl, 10 mM Tris-2-(N-morpholino)propanesulfonic acid (pH 7.5), 5 mM sodium phosphate (pH 7.5), 0.5 mM EDTA, 0.5 mM EGTA as washing buffer, washing buffer with 1 mg/mL BSA, and protease inhibitors as an isolation buffer. The effects of inhibitors on mitochondrial Δψ were determined by fluorescence quenching of the potential-sensitive probe 3,3′-dipropylthiadicarbocyanine iodide DIOC6(3). Mitochondria were mixed with washing buffer with 1 mg/mL BSA, 5 mM MgSO4 and 5 μM DIOC6(3), and the baseline was monitored for 5 min. The reaction was then initiated by adding 5 mM succinate. When the signal had stabilized, compounds were added and proton translocation was measured fluorometrically. Different concentrations of compounds were added to the suspension, and changes in fluorescence due to the disruption of Δψ were continuously monitored with a fluorescence spectrophotometer (FLUOStar Omega; BMG LABTECH) using an excitation wavelength of 643 nm and an emission wavelength of 666 nm.

MD Simulation of Rv3378c. MD simulation of Rv3378c was performed as described previously (71). A total of 12 receptor structures from crystal structures and MD simulations were used in the in silico screening with a library of 1,013 compounds (from NCI diversity set III).

Rv3378c Inhibition. Rv3378 was expressed and purified as described previously (70). The IC50 values for the Rv3378c inhibitors were determined by radiometric assay as follows. Thirteen microliters of 100 nM Rv3378c and inhibitors in the assay buffer (25 mM Tris·HCl, 1 mM MgCl2, 0.01% Triton X-100) was incubated for 10 min at 4 °C. Eighteen microliters of 20 μM tuberculosinyl diphenolate and 40 μM adenosine [0.18% (mole/mole) [2,8-3H] adenosine, 1 μCi/mL; Moravek Biochemicals, Inc.] were then added. The reaction was terminated at 37 °C for ~16–20 h before quenching with 500 μL of saturated NaCl solution. The adenosine in the saline solution was extracted with 500 μL of butanol by vortexing, and 300 μL of the organic layer was transferred into a scintillation vial for counting. IC50 values were obtained from dose–response curves by using Origin 9.0 software.

DSC. The DPPC and DMPA were obtained from Avanti Polar Lipids, and 20 mol% compounds were codissolved with DPPC (DMPA) in chloroform (chloroform/methanol/water). Solvent was removed under a stream of dry nitrogen, and remaining solvent traces were removed in vacuo overnight. Ten microliters of deionized water or sodium phosphate buffer (pH 5, pH 7, or pH 9) was added, and the mixtures were homogenized by hand. Weighed amounts of the mixtures were then sealed into solid sample inserts (stainless-steel tubes). DSC experiments were performed by using a Microcal VP-DSC instrument. Scans covered a 10–70 °C range at a scan rate of 60 °C per hour. The DSC thermograms were analyzed using Origin 7.1. Water vs. water scans were used for baseline correction.

EPR Sample Preparation. Each EPR sample contained DPPC or DMPA lipid with or without a drug (4:1 lipid/drug molar ratio) for a total weight of 3.5 mg. The lipids and drugs were dissolved in either chloroform or 65:35:8 chloroform/methanol/water. A total of 0.05 mg of 5-DOXYL stearic acid or 5-DOXYL stearate methyl ester (both from Sigma-Aldrich) spin label was dissolved in methanol and added to each sample. The solutions were mixed, dried under a nitrogen gas stream until no liquid phase was visible, and then placed under vacuum for 3 h to remove residual solvent. To make a pH-controlled aqueous suspension sample, 500 μL of phosphate buffer (145 mM, pH 7.0) was added. The sample was heated to 65 °C in a water bath, vortexed to form a suspension, and then cooled on ice. Lipids were pelleted by centrifugation at 16,873 × g for 2 min and then cooled on ice again, and 450 μL of supernatant was removed, yielding a 50-μL sample with 7% (wt/vol) lipids and 0.1% spin label. The sample was again heated to 65 °C and mixed thoroughly to form a suspension. The final suspension was injected into a glass tube with an internal diameter of 1.1 mm and stored at −20 °C before spectroscopic experiments.

EPR Spectroscopy. Continuous-wave EPR spectroscopy was performed at X-band (9.14 GHz) using a Varian E-Line Century Series spectrometer with a Varian E-102 microwave bridge. A stable flow (25 L h−1) of nitrogen gas was passed through a cold trap and heated with a Varian 906790-07 variable temperature controller before passing through the EPR sample cavity. The temperature of the sample cavity was monitored with an Omega thermocouple immediately before and after data acquisition; temperature was maintained within ±0.3 °C of the desired value. First-derivative EPR data were obtained with the following parameters: magnetic field scan range = 3,160–3,360 G; field modulation = 2.5 G, modulation frequency = 100 kHz, time constant = 64 μs; total scan time = 6–15 min for each spectrum.

Feng et al. www.pnas.org/cgi/content/short/1521988112
Fig. S1. Calculation of percentage of ΔpH recovery. Percentage of ΔpH recovery is defined as \( I/I_0 \) at a given compound concentration, where \( I_0 \) is the fluorescence intensity decrease on IMV energization and \( I \) the increase after compound addition. The ΔpH recovery percentages from different compound concentrations were used to obtain EC50 values using a standard rectangular hyperbolic dose–response function.

Fig. S2. DSC thermograms for five compounds binding to DMPA: SQ109 (A), amiodarone (B), TMC207 (C), clofazimine (D), and AU1235 (E). \( C_p \), the heat capacity at constant pressure. (F) pH dependence of DSC thermograms of DMPA-SQ109 (2) (20 mol%) at pH 5, pH 7, and pH 9.
Fig. S3. Thirty-nine compounds from the in silico screen tested against Rv3378c. \( IC_{50} \) values obtained are shown. Compounds in red failed the pan-assay interference compounds (PAINS) test (78). The compounds were obtained from the NIH, and their National Service Center code numbers are shown.

Feng et al. www.pnas.org/cgi/content/short/1521988112
Fig. S4. Rv3378c inhibition and uncoupling activity of vacquinol (EcIMV assay).

\[
\begin{align*}
IC_{50} \ (Rv3378c \ inhibition) &= 2.7 \ \mu M \\
EC_{50} \ (EcIMV) &= 12 \ \mu M
\end{align*}
\]

Fig. S5. Thirteen analogs of NSC13316 (37) found by using a similarity search.
Fig. S6. Uncoupler activity of CCCP, lansoprazole (lpz), lansoprazole sulfide (lpzs), and rabeprazole sulfide (rabs) as a function of pH.

<table>
<thead>
<tr>
<th>pH</th>
<th>cccp</th>
<th>lpz</th>
<th>lpzs</th>
<th>rabs</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.6</td>
<td>0.081</td>
<td>719</td>
<td>68</td>
<td>106</td>
</tr>
<tr>
<td>6.3</td>
<td>0.076</td>
<td>957</td>
<td>79</td>
<td>129</td>
</tr>
<tr>
<td>6.1</td>
<td>0.077</td>
<td>711</td>
<td>62</td>
<td>134</td>
</tr>
<tr>
<td>5.8</td>
<td>0.28</td>
<td>1134</td>
<td>64</td>
<td>149</td>
</tr>
<tr>
<td>5.5</td>
<td>0.12</td>
<td>716</td>
<td>130</td>
<td>327</td>
</tr>
</tbody>
</table>
### Table S1. Uncoupling and antibacterial activities for vacquinol and its analogs

<table>
<thead>
<tr>
<th>NSC no.</th>
<th>ΔpH, μM</th>
<th>Cell growth IC&lt;sub&gt;50&lt;/sub&gt; μg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EcIMV</td>
<td>MsIMV</td>
</tr>
<tr>
<td>2450</td>
<td>3.0</td>
<td>3.5</td>
</tr>
<tr>
<td>4377</td>
<td>4.1</td>
<td>3.1</td>
</tr>
<tr>
<td>13097</td>
<td>7.3</td>
<td>6.8</td>
</tr>
<tr>
<td>13316</td>
<td>12</td>
<td>15</td>
</tr>
<tr>
<td>13466</td>
<td>42</td>
<td>21</td>
</tr>
<tr>
<td>13480</td>
<td>11</td>
<td>N.T.</td>
</tr>
<tr>
<td>14224</td>
<td>6.8</td>
<td>12</td>
</tr>
<tr>
<td>16001</td>
<td>6.2</td>
<td>6.9</td>
</tr>
<tr>
<td>23924</td>
<td>14</td>
<td>5.8</td>
</tr>
<tr>
<td>23925</td>
<td>32</td>
<td>N.T.</td>
</tr>
<tr>
<td>146028</td>
<td>300</td>
<td>N.T.</td>
</tr>
<tr>
<td>157571</td>
<td>6.6</td>
<td>N.T.</td>
</tr>
<tr>
<td>305758</td>
<td>4.6</td>
<td>7.7</td>
</tr>
<tr>
<td>305821</td>
<td>31</td>
<td>100</td>
</tr>
</tbody>
</table>

Ms, *M. smegmatis* (100 μM); Mtb, *M. tuberculosis* (50 μM); N.E., no effect at highest concentration tested; NSC, National Service Center; N.T., not tested; Sa, *S. aureus* (100 μM); Sc, *S. cerevisiae* (150 μM).

*From Kitambi et al. (80).*